La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Precigen Gestione

Gestione criteri di controllo 2/4

Precigen's Il CEO è Helen Sabzevari, nominato in Jan2020, e ha un mandato di 4.58 anni. la retribuzione annua totale è $ 3.72M, composta da 26.9% di stipendio e 73.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.77% delle azioni della società, per un valore di $ 2.51M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.6 anni e 10.3 anni.

Informazioni chiave

Helen Sabzevari

Amministratore delegato

US$3.7m

Compenso totale

Percentuale dello stipendio del CEO	26.9%
Mandato del CEO	4.6yrs
Proprietà del CEO	0.8%
Durata media del management	4.6yrs
Durata media del Consiglio di amministrazione	10.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10

The Prognosis On Precigen

Jan 05

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Dec 31

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Helen Sabzevari rispetto agli utili di Precigen?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$135m
Mar 31 2024	n/a	n/a	-US$97m
Dec 31 2023	US$4m	US$1m	-US$96m
Sep 30 2023	n/a	n/a	-US$85m
Jun 30 2023	n/a	n/a	-US$73m
Mar 31 2023	n/a	n/a	-US$79m
Dec 31 2022	US$3m	US$1m	-US$80m
Sep 30 2022	n/a	n/a	-US$84m
Jun 30 2022	n/a	n/a	-US$103m
Mar 31 2022	n/a	n/a	-US$108m
Dec 31 2021	US$3m	US$1m	-US$111m
Sep 30 2021	n/a	n/a	-US$124m
Jun 30 2021	n/a	n/a	-US$125m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	US$20m	US$1m	-US$104m
Sep 30 2020	n/a	n/a	-US$100m
Jun 30 2020	n/a	n/a	-US$122m
Mar 31 2020	n/a	n/a	-US$138m
Dec 31 2019	US$1m	US$500k	-US$169m
Sep 30 2019	n/a	n/a	-US$373m
Jun 30 2019	n/a	n/a	-US$381m
Mar 31 2019	n/a	n/a	-US$414m
Dec 31 2018	US$3m	US$500k	-US$375m

Compensazione vs Mercato: La retribuzione totale di Helen ($USD 3.72M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.41M ).

Compensazione vs guadagni: La retribuzione di Helen è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Helen Sabzevari (62 yo)

4.6yrs

Mandato

US$3,719,061

Compensazione

Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Randal Kirk	Executive Chairman	16.5yrs	US$600.00k	0.40% $ 1.4m
Helen Sabzevari	President	4.6yrs	US$3.72m	0.77% $ 2.6m
Harry Thomasian	Chief Financial Officer	2.8yrs	US$1.13m	0.080% $ 273.0k
Rutul Shah	Chief Operating Officer	no data	US$1.04m	0.073% $ 249.6k
Donald Lehr	Chief Legal Officer & Corporate Secretary	13.6yrs	US$1.06m	0.19% $ 640.4k
Jeffrey Perez	Senior Vice President of Intellectual Property Affairs	10yrs	US$872.09k	0.26% $ 884.3k
Steven Harasym	VP & Head of Investor Relations	6.6yrs	Nessun dato	Nessun dato
Rob Russell	VP & Head of Human Resources	no data	Nessun dato	Nessun dato
Douglas Brough	Senior VP & Head of Research	no data	Nessun dato	Nessun dato
Bryan Butman	Senior VP & Head of CMC	no data	Nessun dato	Nessun dato
Amy Lankford	Senior VP & Head of Clinical Operations and Regulatory Affairs	1.2yrs	Nessun dato	Nessun dato
Phil Tennant	Chief Commercial Officer	less than a year	Nessun dato	Nessun dato

4.6yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di PGEN è considerato esperto (durata media dell'incarico 4.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Randal Kirk	Executive Chairman	16.5yrs	US$600.00k	0.40% $ 1.4m
Helen Sabzevari	President	4.2yrs	US$3.72m	0.77% $ 2.6m
Jeffrey Kindler	Independent Director	12.8yrs	US$319.00k	0.14% $ 468.1k
Fred Hassan	Independent Director	8.2yrs	US$306.50k	0.36% $ 1.2m
Cesar Alvarez	Independent Director	16.5yrs	US$312.50k	0.20% $ 678.2k
James Turley	Lead Independent Director	10.3yrs	US$312.50k	0.16% $ 562.2k
Steven Frank	Independent Director	16.5yrs	US$300.00k	0.36% $ 1.2m
Nancy Agee	Independent Director	less than a year	Nessun dato	0.0061% $ 20.9k
Vinita Gupta	Independent Director	7.3yrs	US$306.50k	0.16% $ 542.2k

10.3yrs

Durata media

69yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di PGEN è composto da personale esperto e esperto (durata media dell'incarico 10.3 anni).

Precigen Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

Precigen, Inc., Annual General Meeting, Jul 05, 2024

President exercised options and sold US$575k worth of stock

Independent Director recently sold US$136k worth of stock

Independent Director recently bought US$688k worth of stock

President exercised options and sold US$58k worth of stock

Recent updates

Consensus revenue estimates fall by 12%

Price target decreased by 41% to US$6.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Shareholder dilution

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Precigen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

New minor risk - Share price stability

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

Price target increased by 11% to US$10.12

Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response

Price target increased by 11% to US$10.12

Precigen, Inc., Annual General Meeting, Jul 05, 2024

Consensus revenue estimates fall by 10%

Price target increased by 40% to US$9.12

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Price target decreased by 27% to US$6.50

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Independent Director recently sold US$136k worth of stock

Forecast to breakeven in 2026

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Independent Director recently bought US$688k worth of stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

President exercised options and sold US$58k worth of stock

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Price target increased to US$14.50

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Precigen names Rutul Shah as chief operating officer

Chief Financial Officer recently bought US$51k worth of stock

Circling Back On Precigen

Independent Director recently sold US$115k worth of stock

Consensus revenue estimates fall by 66%

Independent Director notifies of intention to sell stock

Price target decreased to US$12.00

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen Q2 2022 Earnings Preview

Price target increased to US$13.75

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

Precigen to sell Trans Ova Genetics for $170M upfront